Compare VENUS REMEDIES with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES NOVARTIS VENUS REMEDIES/
NOVARTIS
 
P/E (TTM) x -1.1 494.2 - View Chart
P/BV x 0.1 28.7 0.3% View Chart
Dividend Yield % 0.0 1.6 -  

Financials

 VENUS REMEDIES   NOVARTIS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
NOVARTIS
Mar-18
VENUS REMEDIES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs126758 16.6%   
Low Rs61579 10.6%   
Sales per share (Unadj.) Rs301.8228.4 132.1%  
Earnings per share (Unadj.) Rs-24.931.7 -78.4%  
Cash flow per share (Unadj.) Rs2.532.8 7.8%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs293.3297.1 98.7%  
Shares outstanding (eoy) m12.3424.69 50.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.9 10.6%   
Avg P/E ratio x-3.821.1 -17.8%  
P/CF ratio (eoy) x36.720.4 180.1%  
Price / Book Value ratio x0.32.2 14.2%  
Dividend payout %031.5 0.0%   
Avg Mkt Cap Rs m1,15416,505 7.0%   
No. of employees `0000.90.7 138.5%   
Total wages/salary Rs m3931,445 27.2%   
Avg. sales/employee Rs Th4,026.18,441.3 47.7%   
Avg. wages/employee Rs Th425.02,163.6 19.6%   
Avg. net profit/employee Rs Th-331.81,173.1 -28.3%   
INCOME DATA
Net Sales Rs m3,7245,639 66.0%  
Other income Rs m231,718 1.3%   
Total revenues Rs m3,7477,357 50.9%   
Gross profit Rs m395-63 -631.7%  
Depreciation Rs m33825 1,337.2%   
Interest Rs m35455 640.7%   
Profit before tax Rs m-2751,575 -17.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32792 4.0%   
Profit after tax Rs m-307784 -39.2%  
Gross profit margin %10.6-1.1 -956.5%  
Effective tax rate %-11.550.3 -22.8%   
Net profit margin %-8.213.9 -59.3%  
BALANCE SHEET DATA
Current assets Rs m2,6389,522 27.7%   
Current liabilities Rs m2,3053,296 69.9%   
Net working cap to sales %8.9110.4 8.1%  
Current ratio x1.12.9 39.6%  
Inventory Days Days13537 369.9%  
Debtors Days Days4628 163.0%  
Net fixed assets Rs m4,87146 10,588.6%   
Share capital Rs m123123 100.0%   
"Free" reserves Rs m3,4967,213 48.5%   
Net worth Rs m3,6197,336 49.3%   
Long term debt Rs m1,3740-   
Total assets Rs m7,50911,105 67.6%  
Interest coverage x0.229.5 0.8%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.5 97.7%   
Return on assets %0.67.6 8.4%  
Return on equity %-8.510.7 -79.4%  
Return on capital %1.622.2 7.1%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m061 0.0%   
Fx outflow Rs m5173,630 14.2%   
Net fx Rs m-517-3,570 14.5%   
CASH FLOW
From Operations Rs m5141,610 32.0%  
From Investments Rs m-123687 -17.9%  
From Financial Activity Rs m-387-2,677 14.5%  
Net Cashflow Rs m4-380 -1.1%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 2.0 9.0%  
FIIs % 0.6 1.6 36.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 21.5 308.8%  
Shareholders   20,121 41,647 48.3%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   IPCA LABS  GSK PHARMA  PANACEA BIOTECH  PROCTER & GAMBLE HEALTH  ABBOTT INDIA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 17, 2019 01:45 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS